Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2017 Sep 7;7(1):10760.
doi: 10.1038/s41598-017-11404-9.

Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer

Yi Chen  1 , Jinyu Li  2 , Shixue Chen  2 , Yibao Zhang  3 , Yi Hu  2 , Guoqing Zhang  2 , Xiang Yan  2 , Shunchang Jiao  4
Affiliations
Comparative Study

Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer

Yi Chen et al. Sci Rep. .

Abstract

Albumin-bound paclitaxel (nab-PC) and docetaxel both produced favorable efficacy and safety as first-line therapy in advanced non-small cell lung cancer (NSCLC). However, the comparison between nab-PC and docetaxel remained unclear until now. This retrospective study aimed to compare the efficacy and safety of nab-PC/cisplatin with docetaxel/cisplatin as first-line therapy in advanced NSCLC. 271 patients with advanced NSCLC, who received either nab-PC (55 patients) or docetaxel (216 patients) were reviewed from 2012 to 2016. The primary endpoint was objective overall response rate (ORR). The secondary endpoints were disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and safety profiles. Nab-PC presented a significantly higher ORR than docetaxel (47.3% vs 31.9%; P = 0.033). The difference of ORR was more significantly remarkable in patients with squamous histology (58.3% vs 29.0%; P = 0.007). Additionally, the DCR of nab-PC was significantly higher than docetaxel. Patients in nab-PC group had a trend toward improved PFS and OS compared with patients in docetaxel group, but this didn't reach statistical significance. Grade ≥ 3 neutropenia was less in nab-PC group, while Grade ≥ 3 anemia and thrombocytopenia were less in docetaxel group. Nab-PC/cisplatin as first-line therapy, produced significantly higher efficacy and reduced neutropenia than docetaxel/cisplatin in advanced NSCLC.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Kaplan–Meier curves showing progression-free survival for the patients in the nab-PC group and docetaxel group.
Figure 2
Figure 2
Kaplan–Meier curves showing overall survival for the patients in the nab-PC group and docetaxel group.
See this image and copyright information in PMC

References

    1. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: Male:Female differences diminishing and adenocarcinoma rates rising. INT J CANCER. 2005;117:294. doi: 10.1002/ijc.21183. - DOI - PubMed
    1. Society, A. C. Lung Cancer (Nonsmall cell). 1 (2012).
    1. Ettinger DS, et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:504. doi: 10.6004/jnccn.2017.0050. - DOI - PubMed
    1. Fossella F, et al. Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group. J CLIN ONCOL. 2003;21:3016. doi: 10.1200/JCO.2003.12.046. - DOI - PubMed
    1. Kubota K, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J CLIN ONCOL. 2004;22:254. doi: 10.1200/JCO.2004.06.114. - DOI - PubMed

Publication types

MeSH terms